HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.

Abstract
Vascular endothelial growth factor C (VEGF-C) is a key mediator of lymphangiogenesis, acting via its receptors VEGF-R2 and VEGF-R3. High expression of VEGF-C in tumors correlates with increased lymphatic vessel density, lymphatic vessel invasion, sentinel lymph node metastasis and poor prognosis. Recently, we found that in a chemically induced skin carcinoma model, increased VEGF-C drainage from the tumor enhanced lymphangiogenesis in the sentinel lymph node and facilitated metastatic spread of cancer cells via the lymphatics. Hence, interference with the VEGF-C/VEGF-R3 axis holds promise to block metastatic spread, as recently shown by use of a neutralizing anti-VEGF-R3 antibody and a soluble VEGF-R3 (VEGF-C/D trap). By antibody phage-display, we have developed a human monoclonal antibody fragment (single-chain Fragment variable, scFv) that binds with high specificity and affinity to the fully processed mature form of human VEGF-C. The scFv binds to an epitope on VEGF-C that is important for receptor binding, since binding of the scFv to VEGF-C dose-dependently inhibits the binding of VEGF-C to VEGF-R2 and VEGF-R3 as shown by BIAcore and ELISA analyses. Interestingly, the variable heavy domain (V(H)) of the anti-VEGF-C scFv, which contains a mutation typical for camelid heavy chain-only antibodies, is sufficient for binding VEGF-C. This reduced the size of the potentially VEGF-C-blocking antibody fragment to only 14.6 kDa. Anti-VEGF-C V(H)-based immunoproteins hold promise to block the lymphangiogenic activity of VEGF-C, which would present a significant advance in inhibiting lymphatic-based metastatic spread of certain cancer types.
AuthorsMatthias Rinderknecht, Alessandra Villa, Kurt Ballmer-Hofer, Dario Neri, Michael Detmar
JournalPloS one (PLoS One) Vol. 5 Issue 8 Pg. e11941 (Aug 02 2010) ISSN: 1932-6203 [Electronic] United States
PMID20689828 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Immunoglobulin Heavy Chains
  • Peptide Library
  • Single-Chain Antibodies
  • Vascular Endothelial Growth Factor C
  • Vascular Endothelial Growth Factor Receptor-2
  • Vascular Endothelial Growth Factor Receptor-3
Topics
  • Amino Acid Sequence
  • Antibodies, Monoclonal (chemistry, genetics, immunology, metabolism)
  • Antibody Affinity
  • Antibody Specificity
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Hydrophobic and Hydrophilic Interactions
  • Immunoglobulin Heavy Chains (immunology)
  • Models, Molecular
  • Molecular Sequence Data
  • Mutation
  • Peptide Library
  • Protein Binding (immunology)
  • Protein Multimerization
  • Protein Stability
  • Protein Structure, Quaternary
  • Single-Chain Antibodies (chemistry, genetics, immunology, metabolism)
  • Vascular Endothelial Growth Factor C (chemistry, immunology, metabolism)
  • Vascular Endothelial Growth Factor Receptor-2 (metabolism)
  • Vascular Endothelial Growth Factor Receptor-3 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: